Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
Top Cited Papers
- 1 February 2008
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 9 (2) , 117-123
- https://doi.org/10.1016/s1470-2045(08)70003-2
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Reversible Posterior Leukoencephalopathy Syndrome Induced by RAF Kinase Inhibitor BAY 43-9006Journal of Clinical Oncology, 2006
- A Phase I Trial of an IV-Administered Vascular Endothelial Growth Factor Trap for Treatment in Patients with Choroidal Neovascularization due to Age-Related Macular DegenerationOphthalmology, 2006
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysisBritish Journal of Cancer, 2006
- Angiotensin II Type 1 Receptor Antagonist Candesartan as an Angiogenic Inhibitor in a Xenograft Model of Bladder CancerClinical Cancer Research, 2006
- Nifedipine-Induced Vascular Endothelial Growth Factor Secretion from Coronary Smooth Muscle Cells Promotes Endothelial Tube Formation via the Kinase Insert Domain-Containing Receptor/Fetal Liver Kinase-1/NO PathwayHypertension Research, 2005
- Long-term consequence of renal function following nephrectomy for renal cell cancerInternational Journal of Urology, 2004
- Modifications structurelles et fonctionnelles de la microcirculation dans l???hypertensionDrugs, 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986